3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
2
Endocrine
2
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Conditions
Colorectal Neoplasms
8
Pancreatic Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Ovarian Neoplasms
4
Neoplasms
4
Melanoma
3
Gastrointestinal Neoplasms
3
Cholangiocarcinoma
3
Breast Neoplasms
3
Urinary Bladder Neoplasms
2
Prostatic Neoplasms
2
Neoplasms by Site
2
Multiple Myeloma
2
Hematologic Neoplasms
2
Gallbladder Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Thrombocytosis
1
Thoracic Neoplasms
1
Skin Neoplasms
1
Sarcoma
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Adenocarcinoma
1
Noonan Syndrome
1
Interventions
selpercatinib
3
Trastuzumab
2
Radiotherapy
2
tumor necrosis factor-alpha, CNGRC fusion protein, human
1
trametinib
1
tovorafenib
1
tipifarnib
1
sargramostim
1
pralsetinib
1
mercaptoundecahydrododecaborate
1
entrectinib
1
dabrafenib
1
cobimetinib
1
alectinib
1
aldesleukin
1
Vemurafenib
1
Taxes
1
Tamoxifen
1
Ritonavir
1
Paclitaxel
1
Nivolumab
1
Interleukin-12 Subunit p35
1
Interleukin-12
1
Indinavir
1
Famotidine
1
Doxorubicin
1
Cisplatin
1
Bortezomib
1
4-boronophenylalanine-fructose
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Thyroid Cancer, Papillary
×
cobimetinib
×
Gastrointestinal
×
Clear all
NCT05768178
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled